{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:15:27Z","timestamp":1785896127131,"version":"3.56.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,1,12]],"date-time":"2012-01-12T00:00:00Z","timestamp":1326326400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s00259-011-2023-6","type":"journal-article","created":{"date-parts":[[2012,1,11]],"date-time":"2012-01-11T18:04:33Z","timestamp":1326305073000},"page":"602-612","source":"Crossref","is-referenced-by-count":66,"title":["Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis"],"prefix":"10.1007","volume":"39","author":[{"given":"Markus","family":"Essler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian C.","family":"G\u00e4rtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frauke","family":"Neff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Blechert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reingard","family":"Senekowitsch-Schmidtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Bruchertseifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Morgenstern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Seidl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,1,12]]},"reference":[{"key":"2023_CR1","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1158\/1078-0432.CCR-08-1203","volume":"15","author":"Y Li","year":"2009","unstructured":"Li Y, Song E, Abbas Rizvi SM, Power CA, Beretov J, Raja C, et al. Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bi-labeled multiple targeted alpha radioimmunoconjugates. Clin Cancer Res. 2009;15:865\u201375.","journal-title":"Clin Cancer Res"},{"key":"2023_CR2","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1158\/0008-5472.CAN-10-1186","volume":"71","author":"D Wild","year":"2011","unstructured":"Wild D, Frischknecht M, Zhang H, Morgenstern A, Bruchertseifer F, Boisclair J, et al. Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN). Cancer Res. 2011;71:1009\u201318.","journal-title":"Cancer Res"},{"key":"2023_CR3","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00259-007-0582-3","volume":"35","author":"S Kn\u00f6r","year":"2008","unstructured":"Kn\u00f6r S, Sato S, Huber T, Morgenstern A, Bruchertseifer F, Schmitt M, et al. Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer. Eur J Nucl Med Mol Imaging. 2008;35:53\u201364.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2023_CR4","doi-asserted-by":"crossref","first-page":"394913","DOI":"10.1155\/2010\/394913","volume":"2010","author":"J Elgqvist","year":"2010","unstructured":"Elgqvist J, Andersson H, Jensen H, Kahu H, Lindegren S, Warnhammar E, et al. Repeated intraperitoneal alpha-radioimmunotherapy of ovarian cancer in mice. J Oncol. 2010;2010:394913.","journal-title":"J Oncol"},{"key":"2023_CR5","doi-asserted-by":"crossref","first-page":"e5715","DOI":"10.1371\/journal.pone.0005715","volume":"4","author":"E Drecoll","year":"2009","unstructured":"Drecoll E, Gaertner FC, Miederer M, Blechert B, Vallon M, M\u00fcller JM, et al. Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide 213Bi-DTPA-[F3]2 into the nucleus of tumor cells. PLoS One. 2009;4:e5715.","journal-title":"PLoS One"},{"key":"2023_CR6","doi-asserted-by":"crossref","first-page":"8941","DOI":"10.1158\/0008-5472.CAN-09-1828","volume":"69","author":"H Song","year":"2009","unstructured":"Song H, Hobbs RF, Vajravelu R, Huso DL, Esaias C, Apostolidis C, et al. Radioimmunotherapy of breast cancer metastases with alpha-particle emitter 225Ac: comparing efficacy with 213Bi and 90Y. Cancer Res. 2009;69:8941\u20138.","journal-title":"Cancer Res"},{"key":"2023_CR7","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1158\/0008-5472.CAN-09-4548","volume":"70","author":"M Lingappa","year":"2010","unstructured":"Lingappa M, Song H, Thompson S, Bruchertseifer F, Morgenstern A, Sgouros G. Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer. Cancer Res. 2010;70:6815\u201323.","journal-title":"Cancer Res"},{"key":"2023_CR8","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.2967\/jnumed.109.065961","volume":"50","author":"B Pfost","year":"2009","unstructured":"Pfost B, Seidl C, Autenrieth M, Saur D, Bruchertseifer F, Morgenstern A, et al. Intravesical alpha-radioimmunotherapy with 213Bi-anti-EGFR-mAb defeats human bladder carcinoma in xenografted nude mice. J Nucl Med. 2009;50:1700\u20138.","journal-title":"J Nucl Med"},{"issue":"4 Suppl","key":"2023_CR9","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/cncr.24793","volume":"116","author":"DE Milenic","year":"2010","unstructured":"Milenic DE, Brady ED, Garmestani K, Albert PS, Abdulla A, Brechbiel MW. Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72. Cancer. 2010;116(4 Suppl):1059\u201366.","journal-title":"Cancer"},{"issue":"19 Pt 2","key":"2023_CR10","doi-asserted-by":"crossref","first-page":"7070s","DOI":"10.1158\/1078-0432.CCR-1004-0017","volume":"11","author":"S Bloechl","year":"2005","unstructured":"Bloechl S, Beck R, Seidl C, Morgenstern A, Schwaiger M, Senekowitsch-Schmidtke R. Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a 213Bi-conjugated monoclonal antibody. Clin Cancer Res. 2005;11(19 Pt 2):7070s\u20134s.","journal-title":"Clin Cancer Res"},{"key":"2023_CR11","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1111\/j.1349-7006.2007.00525.x","volume":"98","author":"R Beck","year":"2007","unstructured":"Beck R, Seidl C, Pfost B, Morgenstern A, Bruchertseifer F, Baum H, et al. 213Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice. Cancer Sci. 2007;98:1215\u201322.","journal-title":"Cancer Sci"},{"key":"2023_CR12","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00259-009-1197-7","volume":"37","author":"J Dahle","year":"2010","unstructured":"Dahle J, Jonasdottir TJ, Heyerdahl H, Nesland JM, Borrebaek J, Hjelmerud AK, et al. Assessment of long-term radiotoxicity after treatment with the low-dose-rate alpha-particle-emitting radioimmunoconjugate (227)Th-rituximab. Eur J Nucl Med Mol Imaging. 2010;37:93\u2013102.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2023_CR13","doi-asserted-by":"crossref","first-page":"4231","DOI":"10.1182\/blood-2010-05-282327","volume":"116","author":"SI Park","year":"2010","unstructured":"Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur DS, Orgun N, et al. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood. 2010;116:4231\u20139.","journal-title":"Blood"},{"issue":"3 Pt 1","key":"2023_CR14","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1158\/1078-0432.CCR-05-1264","volume":"12","author":"JP Norenberg","year":"2006","unstructured":"Norenberg JP, Krenning BJ, Konings IR, Kusewitt DF, Nayak TK, Anderson TL, et al. 213Bi-[DOTA0,Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model. Clin Cancer Res. 2006;12(3 Pt 1):897\u2013903.","journal-title":"Clin Cancer Res"},{"key":"2023_CR15","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1158\/1078-0432.CCR-07-4647","volume":"14","author":"M Miederer","year":"2008","unstructured":"Miederer M, Henriksen G, Alke A, Mossbrugger I, Quintanilla-Martinez L, Senekowitsch-Schmidtke R, et al. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors. Clin Cancer Res. 2008;14:3555\u201361.","journal-title":"Clin Cancer Res"},{"key":"2023_CR16","doi-asserted-by":"crossref","first-page":"9277","DOI":"10.1158\/0008-5472.CAN-10-2029","volume":"70","author":"FE Escorcia","year":"2010","unstructured":"Escorcia FE, Henke E, McDevitt MR, Villa CH, Smith-Jones P, Blasberg RG, et al. Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res. 2010;70:9277\u201386.","journal-title":"Cancer Res"},{"key":"2023_CR17","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1158\/0008-5472.CAN-08-4363","volume":"69","author":"H Nakamae","year":"2009","unstructured":"Nakamae H, Wilbur DS, Hamlin DK, Thakar MS, Santos EB, Fisher DR, et al. Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211. Cancer Res. 2009;69:2408\u201315.","journal-title":"Cancer Res"},{"key":"2023_CR18","doi-asserted-by":"crossref","first-page":"846","DOI":"10.4161\/cbt.6.6.4089","volume":"6","author":"C Raja","year":"2007","unstructured":"Raja C, Graham P, Abbas Rizvi SM, Song E, Goldsmith H, Thompson J, et al. Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biol Ther. 2007;6:846\u201352.","journal-title":"Cancer Biol Ther"},{"key":"2023_CR19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2967\/jnumed.107.046938","volume":"49","author":"MR Zalutsky","year":"2008","unstructured":"Zalutsky MR, Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, et al. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81\u00a0C6. J Nucl Med. 2008;49:30\u20138.","journal-title":"J Nucl Med"},{"key":"2023_CR20","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00259-010-1385-5","volume":"37","author":"D Cordier","year":"2010","unstructured":"Cordier D, Forrer F, Bruchertseifer F, Morgenstern A, Apostolidis C, Good S, et al. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8, Met(O2)11]-substance P: a pilot trial. Eur J Nucl Med Mol Imaging. 2010;37:1335\u201344.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2023_CR21","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1158\/1078-0432.CCR-10-0382","volume":"16","author":"TL Rosenblat","year":"2010","unstructured":"Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, et al. Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res. 2010;16:5303\u201311.","journal-title":"Clin Cancer Res"},{"key":"2023_CR22","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2967\/jnumed.109.062604","volume":"50","author":"H Andersson","year":"2009","unstructured":"Andersson H, Cederkrantz E, B\u00e4ck T, Divgi C, Elgqvist J, Himmelman J, et al. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2 \u2013 a phase I study. J Nucl Med. 2009;50:1153\u201360.","journal-title":"J Nucl Med"},{"key":"2023_CR23","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1088\/0031-9155\/56\/3\/012","volume":"56","author":"J Schwartz","year":"2011","unstructured":"Schwartz J, Jaggi JS, O\u2019Donoghue JA, Ruan S, McDevitt M, Larson SM, et al. Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody. Phys Med Biol. 2011;56:721\u201333.","journal-title":"Phys Med Biol"},{"key":"2023_CR24","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1126\/science.1064126","volume":"294","author":"MR McDevitt","year":"2001","unstructured":"McDevitt MR, Ma D, Lai LT, Simon J, Borchardt P, Frank RK, et al. Tumor therapy with targeted atomic nanogenerators. Science. 2001;294:1537\u201340.","journal-title":"Science"},{"key":"2023_CR25","doi-asserted-by":"crossref","first-page":"6288","DOI":"10.1021\/ac0580114","volume":"77","author":"C Apostolidis","year":"2005","unstructured":"Apostolidis C, Molinet R, Rasmussen G, Morgenstern A. Production of Ac-225 from Th-229 for targeted alpha therapy. Anal Chem. 2005;77:6288\u201391.","journal-title":"Anal Chem"},{"key":"2023_CR26","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.apradiso.2004.06.013","volume":"62","author":"C Apostolidis","year":"2005","unstructured":"Apostolidis C, Molinet R, McGinley J, Abbas K, M\u00f6llenbeck J, Morgenstern A. Cyclotron production of Ac-225 for targeted alpha therapy. Appl Radiat Isot. 2005;62:383\u20137.","journal-title":"Appl Radiat Isot"},{"key":"2023_CR27","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1083\/jcb.200304132","volume":"163","author":"S Christian","year":"2003","unstructured":"Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol. 2003;163:871\u20138.","journal-title":"J Cell Biol"},{"key":"2023_CR28","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1667\/RR1371.1","volume":"171","author":"N Chouin","year":"2009","unstructured":"Chouin N, Bernardeau K, Davodeau F, Cherel M, Faivre-Chauvet A, Bourgeois M, et al. Evidence of extranuclear cell sensitivity to alpha-particle radiation using a microdosimetric model. I. Presentation and validation of a microdosimetric model. Radiat Res. 2009;171:657\u201363.","journal-title":"Radiat Res"},{"key":"2023_CR29","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ecl.2010.12.006","volume":"40","author":"G Nicolas","year":"2011","unstructured":"Nicolas G, Giovacchini G, M\u00fcller-Brand J, Forrer F. Targeted radiotherapy with radiolabeled somatostatin analogs. Endocrinol Metab Clin North Am. 2011;40:187\u2013204.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2023_CR30","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ecl.2010.12.003","volume":"40","author":"DJ Kwekkeboom","year":"2011","unstructured":"Kwekkeboom DJ, de Herder WW, Krenning EP. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am. 2011;40:173\u201385.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2023_CR31","doi-asserted-by":"crossref","first-page":"6144","DOI":"10.1039\/c0dt01599g","volume":"40","author":"JD Correia","year":"2011","unstructured":"Correia JD, Paulo A, Raposinho PD, Santos I. Radiometallated peptides for molecular imaging and targeted therapy. Dalton Trans. 2011;40:6144\u201367.","journal-title":"Dalton Trans"},{"key":"2023_CR32","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2174\/157016310793360684","volume":"7","author":"FI Lin","year":"2010","unstructured":"Lin FI, Iagaru A. Current concepts and future directions in radioimmunotherapy. Curr Drug Discov Technol. 2010;7:253\u201362.","journal-title":"Curr Drug Discov Technol"},{"key":"2023_CR33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2217\/imt.10.114","volume":"3","author":"RM Sharkey","year":"2011","unstructured":"Sharkey RM, Goldenberg DM. Cancer radioimmunotherapy. Immunotherapy. 2011;3:349\u201370.","journal-title":"Immunotherapy"},{"key":"2023_CR34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2174\/156720111793663651","volume":"8","author":"H Song","year":"2011","unstructured":"Song H, Sgouros G. Radioimmunotherapy of solid tumors: searching for the right target. Curr Drug Deliv. 2011;8:26\u201344.","journal-title":"Curr Drug Deliv"},{"key":"2023_CR35","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s00259-010-1639-2","volume":"38","author":"C Seidl","year":"2011","unstructured":"Seidl C, Z\u00f6ckler C, Beck R, Quintanilla-Martinez L, Bruchertseifer F, Senekowitsch-Schmidtke R. 177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi. Eur J Nucl Med Mol Imaging. 2011;38:312\u201322.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2023_CR36","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1681\/ASN.2004110945","volume":"16","author":"JS Jaggi","year":"2005","unstructured":"Jaggi JS, Seshan SV, McDevitt MR, LaPerle K, Sgouros G, Scheinberg DA. Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters. J Am Soc Nephrol. 2005;16:2677\u201389.","journal-title":"J Am Soc Nephrol"},{"key":"2023_CR37","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.ijrobp.2005.11.036","volume":"64","author":"JS Jaggi","year":"2006","unstructured":"Jaggi JS, Seshan SV, McDevitt MR, Sgouros G, Hyjek E, Scheinberg DA. Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys. Int J Radiat Oncol Biol Phys. 2006;64:1503\u201312.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2023_CR38","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1158\/0008-5472.CAN-04-3096","volume":"65","author":"JS Jaggi","year":"2005","unstructured":"Jaggi JS, Kappel BJ, McDevitt MR, Sgouros G, Flombaum CD, Cabassa C, et al. Efforts to control the errant products of a targeted in vivo generator. Cancer Res. 2005;65:4888\u201395.","journal-title":"Cancer Res"},{"key":"2023_CR39","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1021\/bc100574f","volume":"22","author":"J Woodward","year":"2011","unstructured":"Woodward J, Kennel SJ, Stuckey A, Osborne D, Wall J, Rondinone AJ, et al. LaPO4 nanoparticles doped with actinium-225 that partially sequester daughter radionuclides. Bioconjug Chem. 2011;22:766\u201376.","journal-title":"Bioconjug Chem"},{"key":"2023_CR40","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1007\/s00259-004-1653-3","volume":"32","author":"C Seidl","year":"2005","unstructured":"Seidl C, Schr\u00f6ck H, Seidenschwang S, Beck R, Schmid E, Abend M, et al. Cell death triggered by alpha-emitting 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death. Eur J Nucl Med Mol Imaging. 2005;32:274\u201385.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2023_CR41","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1158\/1535-7163.MCT-07-0132","volume":"6","author":"C Seidl","year":"2007","unstructured":"Seidl C, Port M, Gilbertz KP, Morgenstern A, Bruchertseifer F, Schwaiger M, et al. 213Bi-induced death of HSC45-M2 gastric cancer cells is characterized by G2 arrest and up-regulation of genes known to prevent apoptosis but induce necrosis and mitotic catastrophe. Mol Cancer Ther. 2007;6:2346\u201359.","journal-title":"Mol Cancer Ther"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-011-2023-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-011-2023-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-011-2023-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T16:05:18Z","timestamp":1558713918000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-011-2023-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,12]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["2023"],"URL":"https:\/\/doi.org\/10.1007\/s00259-011-2023-6","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,12]]}}}